Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorWashington University School of Medicine

About this trial

This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.

Eligibility criteria

Qualifiers

Must be newly diagnosed with a lesion in the brain with imaging characteristics consistent with glioblastoma multiforme. Scan must have occurred no more than 28 days prior to enrollment.

Lesion must be > 3 cm in maximal dimension on MRI.

Lesion must be in the supratentorial space within 5 cm of the cortical surface.

Lesion must be gadolinium enhancing.

Disqualifiers

Contraindication to MRI.

Previous cranial surgery.

Previous history of cancer and/or cancer treatments.

Coagulopathy within 14 days of enrollment defined as PT/PTT outside of normal parameters and platelets < 100,000/mcL.

Trial design

Treatments tested in this trial

  • Sonobiopsy
  • Research blood
  • Cancer Personalized Profiling
  • Definity®

Treatment groups

40 Participants
are divided into 1 treatment group

Sponsors and collaborators

Washington University School of Medicine

Lead sponsor

National Cancer Institute (NCI)

Collaborator